Secukinumab treatment of hidradenitis suppurativa: questions remain - Authors' reply

Lancet. 2024 Feb 17;403(10427):617-618. doi: 10.1016/S0140-6736(23)01615-X.

Authors

Alexa B Kimball¹, Shoba Ravichandran²; SUNSHINE and SUNRISE trial teams

Affiliations

¹ Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA. Electronic address: [email protected].
² Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

PMID: 38368012
DOI: 10.1016/S0140-6736(23)01615-X

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Hidradenitis Suppurativa* / drug therapy
Humans

Substances

secukinumab
Antibodies, Monoclonal, Humanized